QPPV.COM KNOWLEDGE ASSESSMENT

Elexacaftor: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Elexacaftor: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which interpretation best describes the complementary pharmacological roles of the three medicines in the studied regimen?
Question 2 of 10 A patient taking the regimen starts a strong CYP3A inducer. What is the principal pharmacological concern?
Question 3 of 10 A patient with hepatic impairment is being considered for treatment in an EU setting. Which approach best reflects the article’s regulatory guidance?
Question 4 of 10 A patient has two CFTR variants known to prevent production of CFTR protein. What is the most appropriate expectation when considering a corrector-based regimen?
Question 5 of 10 An application to extend a granule formulation to a younger age group is withdrawn. What should be inferred about the existing authorisation?
Question 6 of 10 A patient’s sweat chloride falls substantially after treatment, but long-term survival outcomes have not been measured in that patient. Which interpretation is most appropriate?
Question 7 of 10 A patient’s respiratory symptoms improve on treatment but established bronchiectasis remains. Which interpretation is most appropriate?
Question 8 of 10 How should an ICSR involving a fixed-dose CFTR-modulator combination generally identify the suspect treatment?
Question 9 of 10 A pregnancy exposure report includes a maternal adverse outcome. Which follow-up is most appropriate?
Question 10 of 10 What is a key limitation of using long-term registry data to assess outcomes after pivotal trials?

Select an answer to continue.

QPPV.com